tarlatamab
Sponsor Amgen INC · listed as AMGN
READOUT
Phase 3
Confidence: medium
Source: clinicaltrials
Next catalyst
Event typeREADOUT
Expected date2027-07-05
As disclosedJul 5, 2027
Date precisionday
Confidencemedium
Trial & sponsor
Trial (NCT)NCT06211036
PhasePHASE3
StatusACTIVE_NOT_RECRUITING
Lead sponsorAmgen
Listed asAMGN
Condition(s)Extensive-Stage Small-Cell Lung Cancer; Small-Cell Lung Cancer
!
Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.
This is one row of the free CSA sample. The full snapshot carries 2,103 forward catalysts across 139 listed sponsors.
Get the full dataset — $499 → More AMGN catalysts